bioMerieux (BIM) AI Stock Analysis

• Market Cap: €12.86B
• Dividend Yield: 0.83%
• Average Volume (3M): 107.98K
• Price to Earnings (P/E): 34.0
• Beta (1Y): 0.53
• Revenue Growth: 8.28%
• EPS Growth: -8.08%
• Country: FR
• Employees: 14,147
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.35
• Shares Outstanding: 118,361,220
• 10 Day Avg. Volume: 122,242
• 30 Day Avg. Volume: 107,982
• PEG Ratio: 1.34
• Price to Book (P/B): 2.90
• Price to Sales (P/S): 3.06
• P/FCF Ratio: 37.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €122.50
• Price Target Upside: 14.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: €123.00 ▲(14.85% Upside)

bioMerieux's strong financial performance is the most significant factor, supported by consistent revenue growth and solid margins. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which weighs down the overall score.

bioMerieux Business Overview & Revenue Model

Company Description

bioMérieux (BIM) is a global leader in in vitro diagnostics, specializing in the development of innovative diagnostic solutions for medical and industrial applications. Founded in 1963 and headquartered in Marcy-l'Étoile, France, the company focuses on providing diagnostic tools to detect infectious diseases, monitor chronic conditions, and ensure food safety. Its core products include a range of assays, instruments, and software solutions that facilitate the rapid and accurate diagnosis of health conditions, contributing to improved patient care and safety.

How the Company Makes Money

bioMérieux generates revenue primarily through the sale of its diagnostic products, which include reagents, instruments, and software. The company operates under a business model that combines direct sales and distribution partnerships to reach a global market. Key revenue streams include the sale of diagnostic kits and consumables, which are used in laboratories and healthcare facilities, as well as the provision of services such as maintenance and support for its diagnostic systems. Additionally, bioMérieux benefits from long-term contracts with hospitals and laboratories, enhancing its revenue stability. Strategic partnerships with other healthcare companies and research institutions further contribute to its earnings by expanding its product offerings and market reach. Overall, the company's focus on innovation and quality in diagnostic solutions positions it well within the growing healthcare sector.

bioMerieux Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

bioMerieux Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 107.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Neutral. The current price of 107.1 is below the 20-day moving average (MA) of 107.20, below the 50-day MA of 108.51, and below the 200-day MA of 115.58, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 56.93 is Neutral, neither overbought nor oversold. The STOCH value of 94.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BIM.

bioMerieux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
SAN	75 Outperform	€99.78B	11.15	8.39%	4.76%	-9.82%	119.10%
BIM	66 Neutral	€12.86B	34.00	9.69%	0.83%	8.28%	-8.08%
ERF	64 Neutral	€11.25B	26.36	11.27%	0.97%	6.25%	18.93%
DIM	61 Neutral	€19.88B	75.33	6.65%	0.31%	7.72%	53.84%
ALERS	55 Neutral	€243.63M	103.79	1.32%	―	12.47%	-65.87%

bioMerieux Corporate Events

bioMérieux’s VITEK® COMPACT PRO Gains FDA Approval to Combat Antibiotic Resistance

bioMérieux has received 510(k) authorization from the FDA for its VITEK® COMPACT PRO system, designed to enhance the identification of microorganisms and antibiograms in both clinical and industrial settings. This system aims to address the growing challenge of antibiotic resistance by providing rapid, accurate diagnostics, improving laboratory efficiency, and promoting the proper use of antibiotics. The VITEK® COMPACT PRO is set to launch globally in 2025, offering advanced ergonomics and automation to small and medium-sized laboratories, thus strengthening bioMérieux’s position as a leader in microbiology innovation.